NeuroSense Therapeutics Ltd.
NRSNHealthcare|Biotechnology|IL
$1.68
+0.28 (+20.43%)
Cash / Share
$0.18
Financials
Financial Snapshot
Market Cap
$3.2M
Enterprise Value
$3.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$11.1M
Cash & Investments
$231.0K
Net Cash
$231.0K
Free Cash Flow (TTM)
-$3.7M
Operating CF (TTM)
-$3.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$231.0K
Quarterly Burn
$918.3K
Monthly Burn
$306.1K
Est. Runway
~0.3 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $895.0K | $699.0K | $11.1M | $7.1M | $2.6M | $3.4M | $166.0K | $231.0K | |
| Operating Cash Flow | -$582.0K | -$695.0K | -$1.5M | -$7.6M | -$8.4M | -$10.1M | -$7.7M | -$3.7M | |
| Free Cash Flow | -$589.0K | -$704.0K | -$1.6M | -$7.7M | -$8.4M | -$10.1M | -$7.7M | -$3.7M | |
| Capital Expenditure | -$7.0K | -$9.0K | -$17.0K | -$70.0K | -$29.0K | -$3.0K | -$8.0K | -$3.0K | |
| Financing Cash Flow | $1.4M | $508.0K | $11.9M | $3.7M | $4.0M | $10.9M | $4.4M | $3.1M |
R&D Spending
R&D (TTM)
$6.2M
R&D Intensity
—
R&D Growth vs Prior
+0.0%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $898.0K | $2.5M | $3.1M | $6.4M | $7.3M | $5.7M | $6.2M | $6.2M | |
| SG&A | $337.0K | $393.0K | $2.5M | $7.0M | $4.8M | $4.2M | $4.9M | $4.9M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $89.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$89.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $898.0K | $2.5M | $3.1M | $6.4M | $7.3M | $5.7M | $6.2M | $6.2M | |
| SG&A | $337.0K | $393.0K | $2.5M | $7.0M | $4.8M | $4.2M | $4.9M | $4.9M | |
| Operating Income | -$1.2M | -$2.9M | -$5.6M | -$13.6M | -$12.0M | -$9.9M | -$11.1M | -$11.1M | |
| Interest Expense | $5.0K | $0.00 | $1.2M | $15.0K | $550.0K | $311.0K | $0.00 | $17.0K | |
| Pretax Income | -$1.2M | -$2.8M | -$4.0M | -$12.3M | -$10.1M | -$10.2M | -$11.1M | -$11.1M | |
| Net Income | -$1.2M | -$2.8M | -$4.0M | -$12.3M | -$10.1M | -$10.2M | -$11.1M | -$11.1M | |
| EPS (Diluted) | -4.40 | -10.20 | -4.60 | -21.40 | -16.60 | -11.00 | -8.80 | -8.91 | |
| EBITDA | $13.0K | -$2.8M | -$2.9M | -$12.2M | -$9.6M | -$9.9M | -$11.1M | -$11.1M | |
| Shares Out. (M) | 0.27 | 0.28 | 0.54 | 0.58 | 0.68 | 0.93 | 1.27 | 1.28 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $895.0K | $699.0K | $11.1M | $3.5M | $2.6M | $3.4M | $166.0K | $231.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $3.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $913.0K | $729.0K | $11.4M | $7.4M | $2.9M | $4.4M | $778.0K | $844.0K | |
| Total Assets | $955.0K | $779.0K | $11.4M | $7.7M | $3.2M | $4.6M | $1.0M | $896.0K | |
| Total Current Liabilities | $37.0K | $120.0K | $597.0K | $1.7M | $3.5M | $2.0M | $2.5M | $3.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $37.0K | $120.0K | $2.4M | $2.1M | $4.9M | $2.0M | $2.6M | $3.0M | |
| Stockholders' Equity | $918.0K | $659.0K | $9.0M | $5.6M | -$1.8M | $2.6M | -$1.6M | -$2.1M | |
| Retained Earnings | -$1.6M | -$4.4M | -$8.4M | -$20.8M | -$26.1M | -$36.7M | -$47.8M | -$51.3M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$582.0K | -$695.0K | -$1.5M | -$7.6M | -$8.4M | -$10.1M | -$7.7M | -$3.7M | |
| Capital Expenditure | -$7.0K | -$9.0K | -$17.0K | -$70.0K | -$29.0K | -$3.0K | -$8.0K | -$3.0K | |
| Free Cash Flow | -$589.0K | -$704.0K | -$1.6M | -$7.7M | -$8.4M | -$10.1M | -$7.7M | -$3.7M | |
| Investing Cash Flow | -$26.0K | -$9.0K | -$17.0K | -$3.5M | $3.5M | $1.0K | -$8.0K | $5.0K | |
| Financing Cash Flow | $1.4M | $508.0K | $11.9M | $3.7M | $4.0M | $10.9M | $4.4M | $3.1M | |
| Issuance of Stock | $1.4M | $508.0K | $9.9M | $3.9M | $4.0M | $11.3M | $4.6M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $1.2M | -$79.0K | -$80.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $611.0K | $2.1M | $4.2M | $5.1M | $1.5M | $557.0K | $2.1M | $1.8M | |
| Net Change in Cash | $809.0K | -$196.0K | $10.4M | -$7.5M | -$903.0K | $738.0K | -$3.2M | -$501.4K |
Dilution Tracker
Shares outstanding grew 361.7% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+361.7%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.27 | 0.28 | 0.54 | 0.58 | 0.68 | 0.93 | 1.27 | 1.28 | |
| Change vs Prior % | — | 1.2% | 96.7% | 6.0% | 18.6% | 36.4% | 37.0% | 0.3% | |
| Stock Issuance | $1.4M | $508.0K | $9.9M | $3.9M | $4.0M | $11.3M | $4.6M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $611.0K | $2.1M | $4.2M | $5.1M | $1.5M | $557.0K | $2.1M | $1.8M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -133.7% | -429.1% | -44.9% | -219.6% | 574.6% | -395.3% | 713.1% | 611.0% | |
| ROA % | -128.5% | -363.0% | -35.4% | -160.1% | -317.3% | -223.2% | -1082.2% | -978.9% | |
| ROIC % | -134.5% | -438.2% | -51.6% | -224.1% | 5877.6% | -372.8% | 797.5% | 415.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -133.8% | -93.5% | -142.6% | 11.1% | 17.8% | -11.9% | |
| Net Income | 0.0% | -130.5% | -42.9% | -205.4% | 18.1% | -1.0% | -9.0% | |
| EPS (Diluted) | 0.0% | -131.8% | 54.9% | -365.2% | 22.4% | 33.7% | 20.0% | |
| Operating Cash Flow | 0.0% | -19.4% | -121.4% | -392.9% | -10.1% | -21.3% | 24.3% | |
| Free Cash Flow | 0.0% | -19.5% | -121.0% | -392.0% | -9.5% | -20.9% | 24.3% | |
| R&D Expense | 0.0% | 177.8% | 23.5% | 108.2% | 13.4% | -21.7% | 9.3% | |
| SG&A Expense | 0.0% | 16.6% | 537.4% | 181.3% | -32.2% | -12.0% | 15.6% | |
| Total Assets | 0.0% | -18.4% | 1367.4% | -32.6% | -58.7% | 43.6% | -77.5% | |
| Book Value / Share | 0.0% | -29.1% | 594.8% | -41.1% | -126.4% | 207.7% | -144.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -32.7% | -48.6% | 132.9% | |
| Diluted Shares | 0.0% | 1.2% | 96.7% | 6.0% | 18.6% | 36.4% | 37.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-1.02
10Y Low / Med / High2.50 / 8.64 / 33.83
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.18
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -18.36 | -7.92 | -10.70 | -1.14 | -0.95 | -2.18 | -1.75 | -0.24 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 24.00 | 33.83 | 2.97 | 2.50 | -6.09 | 8.64 | -12.56 | -1.02 | |
| EV/EBITDA | 1626.09 | -7.65 | -5.42 | -0.88 | -0.85 | -1.93 | -1.76 | -0.34 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-123.31
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $714.1K | $3.3M | $10.0M |
| Net Income | -$6.8M | -$5.9M | -$9.7M |
| EPS | $-5.05 | $-4.67 | $-7.58 |
| # Analysts (EPS) | 2 | 2 | 2 |